Podcasts about Bayer

Are multivitamins bad for you? How could that be? In this video, I'll share the truth about the multivitamin scam. Find out about the vitamins you should never take, supplements that don't work, and the harmful ingredients in your supplements. 0:00 Introduction: Multivitamins truth0:19 Harmful ingredients in supplements 1:45 Synthetic vs. natural vitamins 3:38 Do multivitamins really work?9:32 Natural vitamins and minerals11:17 Fake vitamins exposed! Many multivitamins are made with the cheapest, synthetic ingredients which could be doing more harm than good.The first ingredient in many multivitamins is often calcium carbonate, which is limestone! The first ingredient usually makes up the majority of the product. Magnesium oxide, another common ingredient, is very cheap and has the lowest absorption rate compared to other forms of magnesium. The term “natural” isn't regulated, so ingredients derived from sources such as petroleum and coal tar can be labeled as natural. In nature, vitamins don't exist alone; they are combined with other nutrients and cofactors, which are often missing when you take synthetic vitamins. Biochemistry can not work without cofactors. Although there are nutrients that are difficult to obtain in sufficient amounts from food, that doesn't mean they should be replaced with synthetic multivitamins.Maltodextrin is commonly used as a filler in vitamins and minerals. It's a highly refined industrial starch, classified as a complex carbohydrate, and spikes blood sugar more than sugar. Ascorbic acid is a synthetic part of the vitamin C complex. Approximately 90% is made in China from GMO corn and sulfuric acid. Many people have a genetic issue converting cyanocobalamin, a synthetic form of B12, and folic acid, a synthetic form of B9, into their active forms. This can cause negative side effects in 40% of the population.Almost all of the popular multivitamins are owned by Big Pharma, Big Food, Big Chemical, or large investment groups. For example, Centrum Silver is owned by Pfizer, and One a Day is owned by Bayer. Nature Made is owned by the same company that sells Abilify!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Pfizers Abschied von Biontech, eine letzte Enttäuschung für Wirecard-Aktionäre und den Siemens-Absturz. Außerdem geht es um Tesla, Nvidia, Broadcom, Alphabet, Amazon, Cloudflare, Siemens Healthineers, Siemens Energy, Rolls-Royce, Airbus, Boeing, Volkswagen, Merck, Gilead, Johnson&Johnson, Eli Lilly, Bayer, Merck KGaA, Xtrackers MSCI World Health Care ETF (WKN: 113FD), VanEck Morningstar Developed Markets Dividend Leaders (WKN: A2JAHJ), iShares Stoxx Global Select Dividend 100 (WKN: A0F5U), Fidelity Emerging Markets Quality Income ETF (WKN: A2PQDRI), Invesco FTSE EM High Dividend Low Volatility ETF (WKN: A2AHZU) Invesco und den Euro Stoxx High Dividend Low Volatility (WKN: A2ABHF) . Hier findet ihr den BYD-Aktiensplit-Artikel von Lea: https://www.welt.de/wirtschaft/plus68a8494d5d3e123a945a783f/BYD-Aktiensplit-Was-Anleger-nach-dem-Steuer-Aerger-jetzt-wissen-muessen-und-tun-koennen.html Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

En el Radar Empresarial, Capital Intereconomía ha puesto hoy el foco en Ubisoft, en un momento clave para la compañía por su proceso de recuperación operativa y su posición en la industria del videojuego. En el consultorio de Investing, Carlos González (Investing.com España) ha analizado el comportamiento de los principales índices en la recta final de la semana, con especial atención al Ibex 35, que encadena varios máximos históricos. También se ha evaluado el resultado de ACS, tanto desde el punto de vista fundamental como de valoración, y se han respondido preguntas de la audiencia sobre Inditex, Iberdrola, Bayer, Acciona, y compañías con potencial de crecimiento. Investing Pro ha aportado sus listas de valores infravalorados y sobrevalorados para identificar oportunidades y riesgos, especialmente entre las grandes tecnológicas a la espera de los resultados de NVIDIA la próxima semana. Incluso se ha recurrido a Warren AI para contrastar valoraciones. En el Foro de la Inversión, Pablo López Gil-Albarellos (Trade Republic) ha analizado tendencias de inversión y comportamiento del ahorrador europeo. La jornada ha cerrado con Cripto Capital, donde Enrique Palacios (Bit2Me) ha detallado la importancia de la autorización de la CNMV para que Bit2Me STX se transforme en agencia de valores, un avance clave para la institucionalización del sector cripto en España.

Bundesregierung einigt sich auf Reform des Wehrdienstes, Jugendliche ab Jahrgang 2008 müssen zur Musterung erscheinen, Brandbrief von Wirtschaftsverbänden über geplante Finanzierung der künftigen Renten, EU-Kommission lockert das 2024 beschlossene Lieferkettengesetz, Forschergruppe "Global Carbon Project" errechnet weltweit höchsten CO2-Ausstoß, Zehnter Jahrestag der Terroranschläge in Paris mit 130 Toten, WM-Qualifikation: Abschlusstraining der Fußball-Nationalmannschaft, Das Wetter Korrektur: Diese Sendung wurde nachträglich bearbeitet. In der 20 Uhr vom 13.11.2025 haben wir den Fußballspieler Jonathan Tah fälschlicherweise Bayer 04 Leverkusen zugeordnet. Er spielt seit dieser Saison aber bei Bayern München. Diesen Fehler haben wir korrigiert.

Bundesregierung einigt sich auf Reform des Wehrdienstes, Jugendliche ab Jahrgang 2008 müssen zur Musterung erscheinen, Brandbrief von Wirtschaftsverbänden über geplante Finanzierung der künftigen Renten, EU-Kommission lockert das 2024 beschlossene Lieferkettengesetz, Forschergruppe "Global Carbon Project" errechnet weltweit höchsten CO2-Ausstoß, Zehnter Jahrestag der Terroranschläge in Paris mit 130 Toten, WM-Qualifikation: Abschlusstraining der Fußball-Nationalmannschaft, Das Wetter Korrektur: Diese Sendung wurde nachträglich bearbeitet. In der 20 Uhr vom 13.11.2025 haben wir den Fußballspieler Jonathan Tah fälschlicherweise Bayer 04 Leverkusen zugeordnet. Er spielt seit dieser Saison aber bei Bayern München. Diesen Fehler haben wir korrigiert.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Zoff bei den Wirtschaftsweisen, das nächste Palantir und den unendlichen Glyphosat-Fluch bei Bayer. Außerdem geht es um BigBear.ai, Cisco, Xtrackers II Euro Corporates ETF (WKN: DBX0AC), SPDR Bloomberg SASB Euro Corporate Bond ETF (WKN: A2PF0W), Siemens, L'Oréal, ishares Global Corp Bond ETF (WK: A0RGEP), Apple, J&J, Vanguard EUR Corporate Bond UCITS ETF (WKN A2PA8G), Amazon, Alphabet, Nvidia, DWS, Amundi, BlackRock, Commerzbank, Deutsche Bank, ING und BNP Paribas. Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. AMD will stärker wachsen, Infineon ist optimistisch und Foxconn verdient mehr als gedacht - der KI sei jeweils Dank. On wächst besonders stark in Asien, RWE überzeugt und Bayer spart gut. Ledger will an die Börse, Coinbase nicht kaufen und Circle enttäuscht. 70-Mrd.-$-Konzern AON (WKN: A2P2JR) verkauft nicht selbst Versicherungen, sondern vermittelt Kunden die passende Versicherung von anderen Firmen. Heißt: Risiko niedrig, Umsätze stabil. Ein Shortseller hat seit Ende 2024 gegen Strategy (WKN: 722713) gewettet. Jetzt hat er die Position geschlossen. Probleme hat der Konzern, der gerne eigene Aktien verkauft und Bitcoins kauft, trotzdem. Diesen Podcast vom 13.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Beleggers keken deze week uit naar de beleggersdag van Adyen, waarop het bedrijf de nieuwe doelstellingen presenteerde. "Niet héél ambitieus, die doelstellingen", vindt Thomas Pellegrom van ABN Amro. Toch begrijpt hij de positieve reactie van beleggers. "Het zijn nog steeds mooie marges, en Adyen doet het heel goed als je het vergelijkt met Fiserv. Die Amerikaanse concurrent verloor de helft van z'n waarde op beroerde cijfers." Joost van Leenders van Van Lanschot Kempen zit op hetzelfde spoor. "Ik denk dat de doelstellingen bewust conservatief zijn gehouden, om tegenvallers uit te sluiten. Met een koerswinstverhouding van 26 is het aandeel niet extreem gewaardeerd en het is een hele sterke speler in de betalingssector. Over het sentiment zijn beide experts positief, al lijkt de markt op dit moment wat te consolideren. Een AI-bubbel die op springen staat, zo ver is het nog niet en de topspelers in die sector zijn zeer winstgevend Dat niet alleen, ze geven de indices nog steeds de grootste impuls. Verder in de podcast aandacht voor de overname van NIBC door ABN Amro en de cijfers van die laatste. Ook de cijfers van onder andere TKH, Bayer en Aegon worden besproken. De luisteraarsvragen komen aan bod en de experts geven hun tips. Joost tipt deze keer een Amerikaanse bank, Thomas gaat voor een tracker met de ISIN-code IE00B579F325. Geniet van de podcast! Let op: alleen het eerste deel is vrij te beluisteren. Wil je de hele podcast (luisteraarsvragen en tips) horen, wordt dan Premium lid van BeursTalk. Dat kost slechts 9,95 per maand, 99 euro voor een heel jaar. Abonneren kan hier! VanEck ETF’s (advertorial) Deze week is ook weer het tweewekelijks gesprek te beluisteren met Martijn Rozemuller, ceo van VanEckETF’s, de partner van BeursTalk. Met Martijn bespreek ik deze week de praktijk van securities lending. Securities lending komt er simpel gezegd op neer dat, in dit geval, de uitgever van een ETF de onderliggende aandelen uitleent. Uiteraard tegen een vergoeding, die deels terugvloeit naar de eigenaar van de ETF. Dat lijkt mooi, maar er zitten ook bezwaren aan. Get belangrijkste is wel dat er een zogenaamd tegenpartijrisico aan vast zit. Stel dat de lener in de problemen komt en de aandelen niet kan teruggeven, wat dan? We bespreken ook een andere vorm van tegenpartijrisico: de synthetische ETF. Daarbij koopt de uitgever van de ETF niet de aandelen van de index, maar sluit een overeenkomst met een tegenpartij die beloofd de performance van de index te leveren. Ook kier, zo legt Martijn helder uit, speelt natuurlijk het risico dat de financiële tegenpartij in de problemen kan komen. Ter geruststelling: VanEck Europe heeft alleen fysieke ETF's en leent ook geen aandelen uit. Geniet van de podcast! De gepresenteerde informatie door VanEck Asset Management B.V. en de aan haar verbonden en gelieerde bedrijven (samen "VanEck") is enkel bedoeld voor informatie en advertentie doeleinden aan Nederlandse beleggers die Nederlands belastingplichtig zijn en vormt geen juridisch, fiscaal of beleggingsadvies. VanEck Asset Management B.V. is een UCITS-beheerder. Loop geen onnodig risico. Lees de Essentiële Beleggersinformatie of het Essentiële-informatiedocument. Meer informatie? https://www.vaneck.com/nl/nl/ See omnystudio.com/listener for privacy information.

Bundesregierung einigt sich auf Reform des Wehrdienstes, Jugendliche ab Jahrgang 2008 müssen zur Musterung erscheinen, Brandbrief von Wirtschaftsverbänden über geplante Finanzierung der künftigen Renten, EU-Kommission lockert das 2024 beschlossene Lieferkettengesetz, Forschergruppe "Global Carbon Project" errechnet weltweit höchsten CO2-Ausstoß, Zehnter Jahrestag der Terroranschläge in Paris mit 130 Toten, WM-Qualifikation: Abschlusstraining der Fußball-Nationalmannschaft, Das Wetter Korrektur: Diese Sendung wurde nachträglich bearbeitet. In der 20 Uhr vom 13.11.2025 haben wir den Fußballspieler Jonathan Tah fälschlicherweise Bayer 04 Leverkusen zugeordnet. Er spielt seit dieser Saison aber bei Bayern München. Diesen Fehler haben wir korrigiert.

Thu, 13 Nov 2025 13:55:00 +0000 https://jungeanleger.podigee.io/2750-wiener-borse-party-1033-atx-auch-heute-starker-auf-das-legendare-2007er-high-fehlen-38-punkte-gutes-von-mehreren-listed-companies 101bc2bfc930c8546299f66eafa20635 Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #1033: - ATX auch am Donnerstag stärker, auf das legendäre 2007er-High fehlen 38 Punkte - Strabag, Palfinger, Austriacard gesucht - Zahlen von Strabag, Polytec, wienerberger, Austriacard Holdings, - Info und Research zu DO & CO, FACC - DAX schwächer: Merck, Münchener Rück und Bayer gesucht - mehr dazu im Podcast Links:  - Börsepeople morgen: Werner Schrittwieser unter http://www.audio-cd.at/people - PIR wieder am Dienstag http://www.audio-cd.at/private-investor-relations - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? - beim Aktientag 2026 präsentieren (20 Slots, 11 frei): Strabag, Porr, Palfinger, Frequentis, FACC, VIG, Polytec, Semperit, UBM. ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die täglichen Folgen der Wiener Börse Party  (Co-verantwortlich Script: Christine Petzwinkler) im Q4/2025 sind präsentiert von der Börse Frankfurt / Xetra https://www.boerse-frankfurt.de/xetraplus . Infos zum Jingle: https://audio-cd.at/page/podcast/7326 Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 2750 full no Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)

In this episode, Kelly, known as Glyphosate Girl on Instagram, shares her profound experience and knowledge about glyphosate. The conversation begins with Kelly's personal narrative on facing multiple health issues, leading her to explore the adverse effects of glyphosate. The discussion encompasses the origins, widespread use, and dangerous impacts of glyphosate on human health and the environment. Furthermore, Kelly sheds light on Monsanto's controversial practices and the ongoing legal battles. She emphasizes the importance of regenerative agriculture as a solution to move away from reliance on such chemicals.     03:04 Introduction to Glyphosate 03:52 Personal Health Journey 07:05 Discovering Glyphosate's Impact 09:32 History and Use of Glyphosate 14:43 Glyphosate in Our Environment 24:24 Health Implications of Glyphosate 27:20 Legal Battles and Public Awareness 28:16 The EPA's Initial Findings on Glyphosate 29:28 Monsanto's Response and Manipulation 30:31 International Agency for Research on Cancer's Findings 32:05 EPA's Controversial Decision 32:43 Political and Regulatory Challenges 38:04 The Role of Regenerative Agriculture 41:56 Bayer's Acquisition and Legal Battles 43:26 Liability Shields and Legislative Efforts 44:55 Public Awareness and Personal Responsibility 51:38 The European Perspective on Glyphosate    

A crisp crash course on announcing your fundraise correctly, including:a good timeline for drafting, reviewing, and sending out the press releasehow to correctly manage stakeholder feedbackand how to maximize the benefits of the announcementThe guest you'll hear from today, Elisheva Marcus, and I met at the Deep Tech Momentum conference in Berlin and connected over nerding out about comms.Elisheva Marcus has an MSc in Biomedical Communication and brings expertise from the San Jose Mercury News, Ada Health, Bayer, and more. Since 2020, she has been the VP of Communications at Earlybird Venture Capital, supporting portfolio founders as a sparring partner. By the way, Earlybird Venture Capital was founded in 1997 and is among the most experienced venture investors in Europe, covering all development and growth stages from pre-seed to growth in industries like fintech, health tech, and deep tech.---LinksConnect with Elli:https://www.linkedin.com/in/elisheva-marcus/Check out Earlybird:https://earlybird.com/Connect with me:https://www.linkedin.com/in/schmidt-marina/Structure of a Strong Press Release or AnnouncementTitleUse active, direct language.Avoid buzzwords.Commit to a single, powerful title (no subtitle).Key Bullet PointsThree concise bullets summarizing the essential news.Designed for quick journalistic scanning.Represent the three to four main ideas the body will expand on.Header InformationInclude date and location.Opening ParagraphStart with a strong, engaging first sentence.Avoid generic or slow openings.Main BodyExpand on the bullet points in a clear, logical flow.Ensure coherence and story progression.Cover the who, what, where, when, and why.Include:Amount raised (with correct denomination)Impact and significanceThe team and why they're the right peopleA quote from leadership or a clientHow the funds will be used and why it's memorableClosing SectionEnd with a short About section or call to action.Provide contact or follow-up information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Robotikfantasie bei Xpeng, die Weihnachtsüberraschung von FedEx und den Shutdown-Schub für Pharma. Außerdem geht es um Merck, Johnson&Johnson, Amgen, CoreWeave, Nvidia, Softbank, Micron, Oracle, Palantir, Merck KGaA, Siemens Healthineers, UPS, Bayer, Amazon, Alphabet, Microsoft, iShares Core MSCI World ETF (WKN: A0RPWH), Amundi MSCI All Country World ETF (WKN: LYX00C), Vanguard S&P 500 ETF (WKN: A1JX53), iShares Nasdaq 100 ETF (WKN: A0YEDL), Amundi Core Stoxx Europe 600 ETF (WKN: LYX0Q0), Xtrackers MSCI Japan ETF (WKN: DBX1MJ), iShares MSCI China ETF (WKN: A2PGQN), Xtrackers Artificial Intelligence & Big Data ETF (WKN: A2N6LC), Alphabet, Apple, Nvidia und Palantir, Euwax Gold II (WKN: EWG2LD), Xetra Gold (WKN: A0S9GB), Global X Infrastructure ETF (WKN: A40E7B), Vanguard FTSE All World (WKN: A2PKXG), SPDR MSCI All Country World ETF (WKN: A1JJTC), Xtrackers MSCI Emerging Markets ETF (WKN: A12GVR), Vanguard FTSE Emerging Markets ETF (WKN: A2PLTC), iShares EUR High Yield Corporate Bond (WKN: A2DUCZ) und PIMCO Euro Short-Term High Yield Corporate Bond (WKN: A2DLP1). Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

APAC stocks traded mixed with the region indecisive amid light fresh catalysts and as participants digested earnings.House Democratic caucus will meet at noon Wednesday in Washington, according to Punchbowl's ShermanUK's Downing Street has launched an extraordinary operation to protect UK PM Starmer amid fears among the PM's closest allies that he is vulnerable to a leadership challenge in the wake of the Budget, according to The Guardian's Crerar.European equity futures indicate a positive cash market open with Euro Stoxx 50 futures up 0.3% after the cash market closed with gains of 1.1% on Tuesday.Looking ahead, highlights include German CPI Final (Oct), Italian Industrial Output (Sep), BoC Minutes (Oct), EIA STEO, OPEC MOMR, Speakers including ECB's Schnabel & de Guindos, Fed's Paulson, Bostic, Williams, Barr, Waller, Miran, Collins; US Treasury Secretary Bessent. Supply from Germany & US, Earnings from E On, Bayer, Infineon, ABN AMRO, Cisco & On.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En el análisis de mercados, Juan Enrique Cadiñanos subrayó que el foco de los inversores sigue puesto en la inteligencia artificial, con fuertes expectativas en torno a AMD, Infineon y Foxconn, pese a las recientes desinversiones en Nvidia. El experto explicó que, aunque el Dow Jones marca récord tras el fin del cierre de Gobierno en EE.UU., la tecnología muestra cierta corrección, reflejo de una rotación temporal hacia sectores más cíclicos. Cadiñanos señaló que el mercado podría mantener un tono lateral alcista a corto plazo, a la espera de los próximos datos macro y de la evolución de los rendimientos de los bonos, mientras la inteligencia artificial y la energía se mantienen como temas dominantes de inversión. El programa cerró con el consultorio de bolsa junto a Miguel Méndez, analista independiente, quien respondió a las consultas de los oyentes sobre valores tecnológicos, energéticos y estrategias defensivas ante la volatilidad de final de año.

Harvest is the finish line for fieldwork, but it's the starting line for storage management. In this Managing for Profit, Nebraska-based Channel Technical Agronomist Kristin Schiff discusses what farmers should be doing to protect grain quality throughout the winter months.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Wed, 12 Nov 2025 12:28:00 +0000 https://jungeanleger.podigee.io/2747-wiener-borse-party-1033-atx-tr-gestern-auf-high-heute-wohl-wieder-und-douglas-adams-spuren-pierer-mobility-porr-und-rbi-gesucht 3e767ebfafb2512d0dcae0697ad98ae9 Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #1032: - ATX am Mittwoch stärker - Pierer Mobility, Porr und RBI gesucht - Zahlenflut von FACC, DO&CO, Semperit, Post - News zu UBM, Reploid, RBI - Partytalk: Douglas Adams und der ATX Total Return - Vintage FACC - DAX stärker: Infineon, Brenntag und Bayer gesucht - mehr dazu im Podcast Links:  - Börsepeople heute: Konrad Pannagger unter http://www.audio-cd.at/people - PIR morgen http://www.audio-cd.at/private-investor-relations - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? - beim Aktientag 2026 präsentieren (20 Slots, 11 frei): Strabag, Porr, Palfinger, Frequentis, FACC, VIG, Polytec, Semperit, UBM. ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die täglichen Folgen der Wiener Börse Party  (Co-verantwortlich Script: Christine Petzwinkler) im Q4/2025 sind präsentiert von der Börse Frankfurt / Xetra https://www.boerse-frankfurt.de/xetraplus . Infos zum Jingle: https://audio-cd.at/page/podcast/7326 Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 2747 full no Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)

Viele Selbständige mit Existenzsorgen, Schwarzarbeit weiter auf hohem Niveau, Bayer erneut mit Glyphosat-Belastung /Autoren:Felix Lincke, Anne Burghard, Moderation:Stephan Lina

Der VfL Wolfsburg ist tief in der Krise und trennt sich von deinem Coach. Vielleicht eine einmalige Chance den VW Konzernverein auf der Liga zu bekommen. Der Kader scheinz zu stark zu sein, jedoch ist die Mannschaft nicht für den Kampf gegen den Abstieg gebaut worden. Der VAR erregt auch diesen Spieltag wieder die Gemüter: Beim Niederrheinderby zwischen Gladbach und Köln kommt es gleich zu mehreren Video-Eingriffen, wobei die Intervention jedes Mal mindestens unglücklich ist. Auch beim Spiel von Union Berlin gegen den FC Bayern kommt es zu einer Millimeter Abseits Entscheidung. Es stellt sich die Frage wie genau das System ist und ob damit nicht zu viel ins das Spiel eingegriffen wird. Die Leverkusener bezwingen Heidenheim mit 6:0 deutlich. Matchwinner ist wieder einmal Ibo Maza. In Liga zwo Punkten Schalke und Paderborn weiter und setztesn sich leicht vom Rest der Liga ab. Die Hertha holt 7 Siege aus den letzten 5 Spieln und schließt zur Spitzengruppe auf. Bei der Qualität der Mannschaft wird es nun spannend zu sehen sein, ob die Berliner sich nachhaltig oben festsetzen können. Wir waren am Wochenende in der Lausitz und haben dort die Niederlage der Cottbusser gegen Osnabrück gesehen. Ein schwaches Top-Spiel, indem der FCE die schlechten Ergebnisse der letzten Woche fortsetzt.

TODAY ON THE ROBERT SCOTT BELL SHOW: Legacy Media's Collapse, Sperm Crisis, Bayer Eyes Glyphosate Exit, Paxil Fraud Lawsuit, Vaccine Religion, Hava Levi, Hava Wellness, Natasha Trenev, Probiotics Pioneer, God Gap Closing and MORE! https://robertscottbell.com/legacy-medias-collapse-sperm-crisis-bayer-eyes-glyphosate-exit-paxil-fraud-lawsuit-vaccine-as-ritual-hava-levi-hava-wellness-natasha-trenev-probiotics-pioneer-god-gap-closing-and-m/https://boxcast.tv/view/legacy-media-collapse-bayer-eyes-glyphosate-exit-paxil-fraud-vaccine-religion-hava-levi-natasha-trenev---the-rsb-show-11-10-25-fpkyji8hgbz1vu05o9o3 Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Pol Boudes, MD, Chief Medical Officer at Rectify Pharma. Rectify Pharma is a biotechnology company pioneering a positive functional modulators (PFM) platform to address the root causes of genetic and protein folding diseases in the liver, cardio-renal-metabolic and neurodegenerative spaces. The company's lead program is in hepatobiliary diseases. Dr. Boudes has more than 30 years of R&D, clinical, medical affairs and biotech leadership experience. He is a board-certified physician in endocrinology and metabolic diseases with specialization in internal medicine and geriatric diseases. Before joining Rectify, Dr. Boudes served as Chief Medical Officer at Galectin Therapeutics and CymaBay Therapeutics, leading pipeline programs and supporting multiple financings. At Amicus Therapeutics, Dr. Boudes pioneered chaperone therapies for lysosomal storage disorders. Earlier in his career, he held senior international positions at Bayer, Wyeth-Ayerst Research (now Pfizer) and Roche, and he currently serves on the board of Protalix Biotherapeutics. Dr. Boudes received his MD from the University of Marseille, France. Tune in to hear about how innovation in hepatobiliary diseases is gaining new momentum, driven by novel approaches to correcting protein misfolding at its source. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of groundbreaking developments that are reshaping the landscape of drug development and patient care. These stories highlight the dynamic nature of the pharmaceutical and biotechnology industries, where scientific advancements and regulatory changes are driving significant shifts.We begin with a crucial milestone in oncology treatment. The FDA has granted approval to Johnson & Johnson's Darzalex Faspro for patients with high-risk smoldering multiple myeloma. This approval is particularly significant as it provides a new therapeutic pathway for individuals with this precursor condition to active multiple myeloma, which previously had few treatment options. The drug works by targeting CD38 proteins on myeloma cells, representing a leap forward in monoclonal antibody treatments for cancer. This decision underscores the FDA's ongoing commitment to expanding treatment options for conditions with high unmet needs, potentially setting a precedent for future approvals in early-stage malignancies.Meanwhile, Gilead Sciences encountered challenges with its oncology pipeline as Trodelvy failed to meet its primary endpoint in a Phase 3 trial for first-line HR+/HER2-negative metastatic breast cancer. This outcome highlights the complexities of oncology drug development, despite previous successes in other indications. Such setbacks remind us of the inherent risks involved in bringing innovative therapies to market.In contrast, Akeso has announced positive data for ivonescimab, a PD-(L)1xVEGF bispecific antibody. The drug demonstrated significant overall survival benefits in patients with previously treated EGFR-mutated non-small cell lung cancer. This advancement underscores the therapeutic potential of bispecific antibodies in cancer immunotherapy, which continue to gain traction as they target multiple pathways involved in tumor growth and immune evasion.Regulatory incentives have also been making waves. The FDA's rollout of the second round of "national priority" voucher winners aims to accelerate drug development timelines, particularly in critical areas such as obesity. Companies like Lilly and Novo Nordisk have been recognized for their efforts, highlighting a broader strategy to bring transformative therapies to market more swiftly.On the corporate front, Bayer's proposed private equity buyout fell through due to insufficient shareholder support, reflecting ongoing financial volatility and strategic recalibrations within biotech firms. Meanwhile, CMS's introduction of a new Medicaid pricing model aims to implement "most-favored nation" pricing strategies to control drug costs, signaling potential shifts in how pharmaceutical companies approach pricing negotiations and reimbursement strategies.Technological advancements are also at the forefront of innovation. Eli Lilly has expanded its AI-driven drug discovery partnership with XtalPi, focusing on antibody development. This collaboration exemplifies how AI is increasingly being integrated into pharmaceutical research to enhance drug discovery processes.Furthermore, China's decision to lift its ban on Illumina's DNA sequencers is expected to facilitate greater access to advanced genomic technologies within the region, fostering innovation in precision medicine.Leadership changes continue to shape industry dynamics. For instance, Recursion Pharmaceuticals is undergoing executive restructuring to better align with evolving market needs and innovation strategies. These changes are crucial for maintaining competitiveness and fostering an environment conducive to scientific breakthroughs.The industry is also witnessing strategic realignmenSupport the show

Toute l'actu des sélections nationales et des championnats anglais, espagnol, italien et allemand avec nos légendaires "Drôles de Dames" : Julien Laurens, Fred Hermel, Polo Breitner et Johann Crochet.

Lange Zeit galt Deutschland als Land der Industrie und Wirtschaftskraft. Mitbegründer dieses Rufes waren Unternehmen aus dem Westen: Krupp, Thyssen, Mannesmann, Bayer. Sie gehören zur sogenannten Deutschland AG, über die der Journalist Konstantin Richter ein Buch geschrieben hat: "300 Männer - Aufstieg und Fall der Deutschland AG". Bei WDR 2 Jörg Thadeusz spricht er darüber, wie die deutsche Wirtschaft aus der Stagnation kommen kann und was die Deutschland AG mit klassischer Musik zu tun hat. Von Konstantin Richter.

Broadcast from KSQD, Santa Cruz on 11-06-2025:>/p> Dr. Dawn interviews Cindy Jackonette and Dr. Michael Alexander about a fundraiser for pancreatic cancer awareness on November 15th at Bargetto Winery from 2-5pm, supporting the Santa Cruz Cancer Benefit Group. Dr. Alexander explains pancreatic cancer has only 10-15% five-year survival rates and is difficult to screen for. Screening involves complex endoscopy procedures examining pancreatic ducts, CT scans and biomarker scans. The disease represents 3% of cancer cases but 8% of deaths. Immune checkpoint inhibitors show limited success except in Lynch syndrome patients with DNA repair defects. The Santa Cruz Cancer Benefit Group donates annually to local cancer organizations and is all volunteer-run with minimal overhead. An emailer asks when her 56-year-old half-African American son should get colon cancer screening given his father and uncle both had the disease. Dr. Dawn explains African Americans have increased risk and recommends immediate colonoscopy despite the ideal screening window being 10 years ago. She emphasizes identifying whether he produces polyps, which would require surveillance every 3-5 years. Unlike pancreatic cancer, colon cancer is highly curable when detected early, with death rates dropping 30-40% since colonoscopies became standard in the mid-1990s. She recommends preventive measures including daily 200mg ibuprofen (if no ulcer history) and a high-fiber diet rich in colorful vegetables containing antioxidants that reduce oxidative stress and DNA damage from free radicals. An emailer from Israel asks about supporting his 38-year-old son's rectal adenocarcinoma treatment. Dr. Dawn recommends nutritional strategies including juicing 10 different fruits and vegetables daily, 20mg melatonin for synergy with chemotherapy, vitamin D supplementation, and L-glutamine as primary food for bowel healing and lymphocyte function. She suggests DHA fish oil to enhance chemotherapy effectiveness, green tea for oncogene inhibition, astragalus herb to increase phagocytic activity and natural killer cells, and rotating water-extracted mushroom formulas with beta-glucans, particularly maitake and shitake. Glutamine also protects mucous membranes from radiation burns. Dr. Dawn discusses alarming cancer rate increases among young adults in Corn Belt states including Iowa, Nebraska, Illinois, Minnesota, Indiana, and Kansas. Since 2015, these states show 5% higher cancer rates for ages 15-49 compared to national averages, with particularly elevated kidney and skin cancer rates. Young women face 66% higher skin cancer risk than peers in other states. . Governor Kim Reynolds invested $1 million for research while Bayer's attempt to shield Roundup from lawsuits failed. Dr. Dawn notes Roundup now contains diquat after removing glyphosate. It has taken decades to accumulate evidence of glyphosates harms, She warns that absence of evidence of Diquats being harmful isn't evidence of safety and that Ames testing suggests high mutation potential. An emailer shares a JAMA article on lithium for Alzheimer's disease. Dr. Dawn explains that calcium dysregulation through NMDA receptors plays an upstream role in Alzheimer's pathology. Lithium, a bipolar disorder treatment, can reset deranged calcium gates, inhibiting mitochondrial damage and tau protein production. She emphasizes tau protein as the true culprit in Alzheimer's while amyloid beta is more symptomatic. Correcting calcium homeostasis allows neuronal autophagy systems to clear waste more efficiently rather than being overwhelmed. She reports dramatic peanut allergy declines following 2017 pediatric recommendations for introducing peanuts at 4-6 months based on the LEAP study showing 81% reduction. Between 2017-2020, peanut allergies dropped from 0.79% to 0.45% of all children under 3, with overall food allergies declining 36%. Studies also show pregnant mothers eating peanuts reduces offspring allergy risk by promoting immune tolerance. We conclude with breakthrough wireless retinal implants for macular degeneration, where cameras on glasses convert images to near-infrared signals to retinal implants which stimulate surviving retinal neurons. The prototype allowed patients to improve by two lines on eye charts and perceive facial expressions and read smaller print.

Der Amazonas-Regenwald spielt eine zentrale Rolle in der Klimakrise. Als stehender, gesunder Wald absorbiert er das Kohlendioxid in der Atmosphäre. Wird der Wald jedoch zerstört, durch Abholzung oder Brände, kehrt der aufgenommene Kohlenstoff in die Atmosphäre zurück. Doch wie finanziert man Waldschutz? Brasiliens Bundesstaat Pará, dort wo am kommenden Montag die UN-Klimakonferenz stattfindet, hat im vergangenen Jahr ein Mega-Projekt angekündigt. 12 Millionen Co2-Zertifikate will der brasilianische Bundesstaat verkaufen und damit rund 180 Millionen US-Dollar einnehmen. Käufer gäbe es auch schon. Nämlich die sogenannte LEAF-Koalition. 2021 vom Konzern Amazon gegründet, gehören ihr nicht nur weitere Unternehmen an, darunter Bayer und H&M, sondern auch Regierungen: die USA, Großbritannien und Norwegen. Doch das Abkommen stößt auf Widerstand. Die Staatsanwaltschaft sprach sich für einen Stopp des Projektes aus, traditionelle Gemeinschaften beklagen, es fehle an Transparenz. Ein Feature unserer ARD-Südamerika-Korrespondentin Anne Herrberg.

This episode covers: Cardiology this Week: A concise summary of recent studies Lp(a) - What to expect in the very near future Myocardial infarction in older and frail adults Mythbusters: is beetroot good for your heart? Host: Rick Grobbee Guests: JP Carpenter, Vijay Kunadian, Erik Stroes Want to watch that episode? Go to: https://esc365.escardio.org/event/2177 Want to watch that extended interview on Lp(a), go to: https://esc365.escardio.org/event/2177?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel, Vijay Kunadian and Erik Stroes have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Paul Brown is an expert at the intersection of creative strategy and technology. He is a Global Client Partner at London-based CreativeX, where he works at the forefront of creative AI. He guides global giants like Mars, Colgate-Palmolive, and Bayer, helping them make their advertising more effective by unlocking the power of creative data. Paul is also passionate about mentorship, and is an Industry Advisor for the Marketing and PR degree at the University of West London.CreativeX recently released their study "Are Creators Really Effective", which outlined how brands can unlock more effectiveness from creator content, and their annual "Gender in Advertising Report" which shows how much and in what way women are being represented in digital advertising.Before joining CreativeX, Paul had a front-row seat to the startup world as the 6th employee and Head of Customer Success at Spirable, a data-driven creative platform that was acquired in 2021. His journey in the industry began in client-facing roles at top creative agencies, including Ogilvy and TMW, giving her/him a deep understanding of what makes brands and their stories succeed.

Asgrow® XtendFlex® soybeans continue to help farmers improve yield and profitability. Seed brands are launching 43 new products for 2026. In this episode of Managing for Profit, Lance Tarochione, Technical Agronomist at Bayer Crop Science, discusses how farmers can make smart seed decisions ahead of the 2026 growing season.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Jody Gander, Technical Product Manager for Crop Protection at Bayer, joins us to share groundbreaking updates on two new herbicide chemistries in development. First up is Icafolin, the first new active ingredient for post-emergence herbicides in over 30 years, offering a novel mode of action to combat herbicide-resistant weeds. We also dive into Conventro, a powerful preemergence herbicide for corn and soybeans. Tune in to learn how these innovations will reshape weed control and support sustainable farming practices.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, join Michael Sullivan, Senior Vice President, Product Supply Chain NA, Bayer and James Hoskins, Vice President, Operations, Life Sciences and Healthcare, DHL Supply Chain, as they explore our 25-year partnership, organizational strategy and successful collaborations. 

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW's Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week's top story came from women's health, as Bayer paved the way for a new approach to treat hot flashes due to menopause. Elsewhere, an anti-obesity medication has health benefits beyond weight loss and Alector discontinued its dementia drug.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The eighth edition of the China International Import Expo is set to open in Shanghai on Wednesday, and some overseas exhibitors have already confirmed participation for next year's event, drawn by the exhibition's role as a premier platform for connecting with the Chinese market and global resources.第八届中国国际进口博览会将于周三在上海开幕，部分海外参展商已确认参加明年的展会。该展会作为连接中国市场与全球资源的顶级平台，吸引了众多参展方。International firms and government agencies said the CIIE clearly demonstrates China's dedication to progressing alongside the world and sharing growth prospects.国际企业和政府机构表示，进博会清晰展现了中国与世界共同发展、共享增长机遇的决心。Premier Li Qiang will attend the opening ceremony of this year's CIIE, which will run through Monday, and deliver a keynote speech, He Ya dong, a spokesman for theMinistry of Commerce, announced on Monday.商务部发言人何亚东周一宣布，李强总理将出席本届进博会开幕式并发表主旨演讲，展会将持续至周一。Leaders from other countries, including Georgian Prime Minister Irakli Kobakhidze, Serbian Prime Minister Djuro Macut, Speaker of the House of Representatives of Nigeria Abbas Tajudeen, and President of the National Council of Slovenia Marko Lotric, will attend the opening ceremony of the CIIE and related events.其他国家领导人也将出席进博会开幕式及相关活动，包括格鲁吉亚总理伊拉克利・科巴希泽（Irakli Kobakhidze）、塞尔维亚总理久罗・马楚特（Djuro Macut）、尼日利亚众议院议长阿巴斯・塔朱丁（Abbas Tajudeen）以及斯洛文尼亚国民委员会主席马尔科・洛特里奇（Marko Lotric）。Herbalife, a Los Angeles, United States-based health and wellness company, is among the exhibitors that have signed up for the ninth CIIE. Having participated in every edition of the expo, the company views it as a vital window for showcasing its global innovations.美国洛杉矶健康与wellness企业康宝莱（Herbalife）已签约参加第九届进博会。该公司连续参展每一届进博会，将其视为展示全球创新成果的重要窗口。Many of the company's products have transitioned from exhibits to commodities. The Herbalife24 sports nutrition product line was first showcased at theinaugural CIIE in 2018. The products were launched in China in 2021, following positive feedback from the expo, and have since realizedlocalized production.康宝莱的多款产品已从展品转变为商品。康宝莱24运动营养系列于2018年首届进博会上首次亮相，经展会反馈良好后，于2021年进入中国市场，目前已实现本地化生产。Stella Tsai, managing director of Herbalife China, said, "We are impressed by China's robust economic development and the improving business environment, which offer stability and vast opportunities for multinational companies."康宝莱中国区总经理蔡美琳（Stella Tsai）表示：“中国强劲的经济发展和持续优化的营商环境令人印象深刻，为跨国企业提供了稳定的发展环境和广阔机遇。”She added that the company's global product innovation center, unveiled last month in Shanghai as an upgrade from its former China product innovation center, aims to swiftly transform Chinese consumers' demands into innovative products, leveraging China's unique consumer insights and innovation environment to impact the Asia-Pacific and global markets.她补充道，公司上月在上海揭牌升级了原中国产品创新中心，成立全球产品创新中心。该中心旨在依托中国独特的消费洞察和创新环境，快速将中国消费者需求转化为创新产品，进而影响亚太及全球市场。The state of Mato Grosso, one of Brazil's keyagricultural commodities and livestock producing regions, will participate in this year's CIIE for the third consecutive year with its own booth, and has confirmed its return next year with an expanded presence.马托格罗索州是巴西重要的农产品和畜牧产品产区，该州将连续第三年独立设展参加本届进博会，并已确认明年扩大规模继续参展。This year's booth of Mato Grosso will double in size to 200 square meters, and the delegation will consist of nearly 70 entrepreneurs and industry leaders led by the Mato Grosso Investment Promotion Agency and the Mato Grosso State Secretariat of Economic Development.今年马托格罗索州的展位面积将翻倍至200平方米，代表团由该州投资促进局和经济发展秘书处牵头，近70名企业家和行业领袖组成。Highlighted exhibits will include those with enormous commercial potential, such as the sesame category recently covered by a new origin export agreement with China, various beans and high-quality local beef.重点展品包括具有巨大商业潜力的产品，如近期与中国达成新原产地出口协议的芝麻品类、各类豆类以及优质本地牛肉。Cesar Miranda, secretary of the Economic Development of Mato Grosso, said: "China is currently our largest trading partner and the primary destination for Mato Grosso's agricultural exports. Participating in the CIIE is crucial for reinforcing this relationship and exploring new investment channels."马托格罗索州经济发展秘书塞萨尔・米兰达（Cesar Miranda）表示：“中国目前是我们最大的贸易伙伴，也是马托格罗索州农产品出口的主要目的地。参加进博会对于巩固这一关系、探索新的投资渠道至关重要。”German multinational company Bayer, another regular participant at the CIIE, expressed unwavering confidence in the Chinese market. He Yong, general manager of Bayer Consumer Health China, noted that the Chinese market's progress toward maturity is similar to that of developed markets.德国跨国企业拜耳（Bayer）也是进博会的常客，该公司对中国市场表达了坚定信心。拜耳消费者健康中国区总经理何勇指出，中国市场的成熟进程与发达市场相似。The general manager said the company's strategic moves, including building various mechanisms and innovation platforms as well as renewing partnerships in China, reflect its substantial confidence in the market's future.何勇表示，公司在中国搭建各类机制和创新平台、深化合作伙伴关系等战略举措，充分体现了对中国市场未来的高度信心。The new supply center project of Bayer Consumer Health in Qidong, Jiangsu province, involves a total investment of 750 million yuan ($105 million), with a gross floor area of about 53,000 sq m. Completion is expected in early 2026.拜耳消费者健康在江苏启东的新供应中心项目总投资7.5亿元人民币（约合1.05亿美元），总建筑面积约5.3万平方米，预计2026年初竣工。"The choice of Qidong for the site is due to its strategic position in the global supply chain. A significant portion of the products produced there will be supplied not just within China, but to a network of global cities that make economic sense for our business," said He.何勇表示：“选择启东作为选址，得益于其在全球供应链中的战略地位。该中心生产的大部分产品不仅将供应中国市场，还将输送至对公司业务具有经济价值的全球城市网络。”Experience from the past editions inspired him to describe the CIIE as a massive platform for multidirectional exchanges. "It serves as a venue for everything from product displays to cutting-edge technologies, covering a wide range of categories from specific product lines to almost all-encompassing areas of exhibitions and connections," he added.何勇补充道：“基于往届参展经验，他将进博会形容为一个大型多向交流平台。“这里既是产品展示的场所，也是前沿技术的交流阵地，覆盖从特定产品线到几乎全方位的展览和对接领域。”The eighth edition of the China International Import Expo第八届中国国际进口博览会Ministry of Commerce商务部inaugural/ɪˈnɑː.ɡjə.rəl/adj.就职的，就任的；首次的，初始的localized production本地化生产agricultural commodities and livestock producing regions农产品和畜牧产品产区

Welcome back to The Bundesliga Show! In this episode, the lads take you through the major talking points from Matchday 9 in the Bundesliga 2025/26! On Friday night, BVB edged past FC Augsburg in an underwheling match at the WWK Arena. Serhou Guirassy provided the only goal in a narrow 1-0 win. On Saturday, RB Leipzig produced a high-quality performance to see off Stuttgart 3-1 at the Red Bull Arena. Diomande was the star, with Romulo also getting on the scoresheet in a deserved home win. FC Bayern thrashed Leverkusen despite dropping Kane and Diaz to the bench. The home side still produced their top form, as they made it 15 straight wins in all competitions ahead of their huge fixture at PSG in the Champions League. On Sunday, there was a thriller between 1. FC Koeln and Hamburger SV, with the home side winning 4-1 in a game that saw Hamburg have 2 goals ruled out as well as two red cards. THe weekend was concluded with another quality match, with Hoffenheim running out 3-2 winners at Wolfsburg. Wouter Burger was the standout performer with a brace.Today the key matches include:FC Bayern Muenchen vs Bayer 04 LeverkusenRB Leipzig vs VfB Stuttgart1. FC Koeln vs Hamburger SVVfL Wolfsburg vs TSG HoffenheimFC St Pauli vs Borussia MoenchengladbachWhich was your favourite match of the week?Which players did you enjoy the most over this match day?Which team will be the most disappointed with their result? #bundesliga #germanfootballclub #bundesligafantasy

Spieltach 9 ist ein Vorbote auf das Rheinderby in der nächsten Woche. Gladbach schafft die Trendwende beim schwachen FC St. Pauli. Köln ist mit dem Sieg gegen Mitaufsteiger HSV weiter im Soll und kommt mit breiter Brust in den Borussia-Park. Die ersten Sticheleien zwischen Yannik und Marcel sind vorprogrammiert.Schwierig wird es für Mainz, die auch gegen Bremen keinen Heimdreier holen. Doch die Leistung gegen ein stabiles Werder macht Hoffnung. Zum Schluss bleibt noch das Topspiel der Bayern: Warum sich Matze von Leverkusen betrogen fühlt und wer Bayern überhaupt noch gefährlich werden - alles dazu in der neuen Folge Spieltach!TIMESTAMPS:(00:00) St Pauli verliert Krisenduell(20:10) Crazy Game im Aufsteigerduell(33:05) Mainzer Heim-Pech gegen Bremer Stabilität(45:35) Bayer(n) Leverkusen(59:10) QuizJETZT PATRON WERDEN:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/derspieltach⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠WERDE TEIL DER COMMUNITY:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/bmsxDkwcqT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠JETZT BEI KICKTIPP TEILNEHMEN:⁠⁠⁠⁠⁠⁠⁠⁠https://kicktipp.de/spieltach⁠

87 Prozent der Unternehmenschefs sagen: Die größte Gefahr für ihre Geschäfte ist die geopolitische Instabilität. Darüber sprechen wir unter anderem mit Bayer-CEO Bill Anderson und Union-Fraktionschef Jens Spahn.

87 Prozent der Unternehmenschefs sagen: Die größte Gefahr für ihre Geschäfte ist die geopolitische Instabilität. Darüber sprechen wir unter anderem mit Bayer-CEO Bill Anderson und Union-Fraktionschef Jens Spahn.

Vidcast:  https://www.instagram.com/p/DQdlztLFFi-/The hot flashes and night sweats of menopause create a miserable midlife for so many women.  Hormones do offer relief, but many women cannot take them.  Enter a new non-hormonal drug just approved by the FDA.This medication, elinzanetant to be marketed as Lynkuet by Bayer, GlaxoSmithKline, and Nerre Therapeutics, is an oral neurokinin/tachykinin antagonist that normalizes thermal and sleep regulation.  A phase 3 multi-national study headed by researchers at the University of Virginia School of Medicine shows that 120 mg elinzanetant taken daily relieves both the frequency and intensity of hot flashes, improves sleep quality, and elevates moods. Improvement occurred for some study participants within the first week of therapy.Last year, the FDA approved another Bayer oral menopause drug fezolinetant, branded as Veozah. With one neurokinin receptor blocker, it reduces hot flashes only. This year's new entry is more powerful as it blocks two neurokinin receptors and affects not only thermoregulation, the hot flashes, but also sleep and mood.Since these drugs contain no estrogen, they lack the risks of blood clots, possible strokes, or exacerbation of certain hormone-dependent cancers including breast, uterine, and ovarian. Once readily available at your pharmacy, they provide safe, effective, and non-hormonal options for controlling bothersome menopausal symptoms.  Currently not approved for women with pre- or peri-menopausal symptoms, that approval should come soon,https://medicalxpress.com/news/2025-10-fda-nonhormonal-drug-ease-menopause.htmlhttps://newsroom.uvahealth.com/2025/09/16/drug-reduces-hot-flashes-by-73-trial-finds/#women #elinzanetant #Lynkuet #menopaue #hotflashes #nightsweats

Welcome to the Refill! Refilling your mind with the latest in mental health and Pharmacy news.This is a new channel (and podcast segment), designed to bring you the latest insights and news in the world of mental health and pharmacy. If you want more tips and conversations about mindfulness, and mental health checkout The Mindful PharmD Podcast on major podcast platforms.Connect with me --> https://drmatmonharrell.bio.link/Music provided by PodcastleReferencesThe Hebrew University of Jerusalem. Popular hair-loss pill linked to depression and suicide. ScienceDaily. October 13, 2025. Available from: https://www.sciencedaily.com/releases/2025/10/251013040343.htmUnknown Author. (2025). Simple screening tool could save a patient's life. Doximity. https://www.doximity.com/articles/7e2b43ef-176d-44ac-ad43-1b857e092232Kansteiner F. With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds. FiercePharma. October 24, 2025. Available from: https://www.fiercepharma.com/pharma/fda-nod-bayers-lynkuet-enters-limited-us-market-nonhormonal-menopause-symptom-meds Vincent, E. & Vincent, B. (2025, October 20). Instagram shows more ‘eating disorder-adjacent' content to vulnerable teens, internal Meta research shows. Reuters. https://www.reuters.com/business/instagram-shows-more-eating-disorder-adjacent-content-vulnerable-teens-internal-2025-10-20/ Subscribe. Share. Rate.A thousand thanks!drmatmonharrell.bio.link Hosted on Acast. See acast.com/privacy for more information.

Der 1. FC Kaiserslautern pirscht sich an die Aufstiegsplätze heran. Was ist Lieberknechts Erfolgsrezept? Und warum kann man am Sonntag gegen Düsseldorf ein Spektakel erwarten? Außerdem: Bayer Leverkusen steht in der nächsten Pokalrunde - aber denkbar knapp. Gegen Paderborn tat sich die Werkself sichtlich schwer. Warum? Und ist Bayer zu abhängig von Unterschiedsspieler Alejandro Grimaldo?

Our Good Friend Kristy Bayer who is the AD at Rockhurst University, is back on the Podcast and we talk about NCAA, NIL, and finding a Good Fit for PSA's - THIS is Wednesday Wisdom on The Educational AD Podcast!

Justin Berg - Technical Product Manager at WestBred Wheat with BAYER talks about several tools they have available to help producers during the off season in preparation for next year. See omnystudio.com/listener for privacy information.

Missouri is one of several states where state officials are working quickly to redraw voting maps to benefit the Trump administration and congressional Republicans before the next election. Those efforts have hit multiple legal obstacles in the Show Me State, including lawsuits and a looming referendum. How these legal battles end could decide the political future of Missouri, and even the country. Erica Slater, Nannette Baker and Michael Wolff analyze those possibilities for this month's Legal Roundtable. The panel also dives into the latest developments in a lawsuit against Bayer, a new lawsuit from a victim of the 2022 CVPA school shooting against BJC Healthcare, and more.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über einen möglichen Handelsfrieden zwischen den USA und China, einen Mega-Deal im Biotech-Sektor und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um Novartis, Bayer, Avidity Biosciences, YPF, Banco Macro, BBVA Argentina, Apple, Amazon, Microsoft, Alphabet, Meta, Porsche Automobil Holding, Baidu, CRISPR THERAPEUTICS, Robinhood, Oklo, Uber, Siemens. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes  What if, instead of giving your team answers, you asked the right questions and listened? In this episode, Kevin sits down with Luciana Núñez to discuss how coaching can be more than just a skill; it can be a leadership philosophy that transforms individuals, teams, and entire organizations. Luciana shares why the command-and-control leadership model no longer works in today's world, and how leading with coaching creates alignment, trust, and engagement. They dive into key concepts from her book, including the “performance equation” (P = C × A²), the power of visualization, and the importance of overcoming biases as a leader. Luciana offers practical insights on how leaders can develop active listening skills, ask powerful questions, and foster greater accountability and resilience in their teams. Listen For 00:00 Introduction: Leading with coaching 01:58 Guest introduction Luciana Nunez 03:05 Luciana's journey from Argentina to executive coaching 05:16 Discovering the power of coaching 05:33 Why Luciana and Tom Preston wrote Coaching Power 07:10 The writing and collaboration process 08:20 Case studies and structure of the book 09:18 Leading with coaching vs being a coach 10:19 Why command and control leadership no longer works 11:24 Listening and asking powerful questions 13:33 The mindset shift from manager to leader 15:09 Checking your biases as a leader 17:06 Staying curious and self aware while coaching 19:11 Helping others visualize success 21:22 Neuroscience and practice of visualization 24:03 The performance equation P = C × A² 26:39 Why attitude is limitless 27:34 Coaching remotely or at a distance 29:30 Creating safety and context in virtual coaching 31:35 Getting to know Luciana personally 33:05 What Luciana is reading The Boiling Frog 35:20 Where to find Luciana and her work 37:38 Wrap up and outro Luciana's Story: Luciana Núñez, co-author of Coaching Power: Lead with Coaching to Create Individual, Team, and Organizational Outperformance, with Tom Preston. She is a partner and Head of Americas at The Preston Associates, one of the world's premier executive coaching firms. An accomplished executive coach and former CEO with more than 20 years of leadership experience at Fortune 500 companies, including Bayer, Danone, and Roche, she blends her strategic expertise with a passion for mentoring, serving as a board member, investor, and advisor to entrepreneurs and executives worldwide. Having lived and worked in multiple continents, Luciana thrives in diverse cross-cultural contexts. She is a Sommelière, an art lover and annual competitor in Spartan obstacle course endurance races. This Episode is brought to you by... Flexible Leadership is every leader's guide to greater success in a world of increasing complexity and chaos.  Book Recommendations Coaching Power: Leading With Coaching to Create Individual, Team, and Organizational Outperformance by Tom Preston and Luciana Nunez  THE BOILING FROG: 21 STRATEGIES TO TRANSFORM STRESS INTO STRENGTH & COMFORT by Ash Kumar MD Like this? The Coaching Effect with Bill Eckstrom How to Deliver Bad News - and Get Away With it! with Mahesh Guruswamy Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group  

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Bizable https://GoBizable.comUntie your business exposure from your personal exposure with BiZABLE.  Schedule your FREE consultation at GoBizAble.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeBig Pharma and the Book of Revelation // Are You TERRIFIED on No King's Day? // David Black's Brand: A Fake Pastor's Viral Moment.Episode Links:Few people know Big Pharma's origin story. So I told @patrickbetdavid. The industry was literally born on cocaine & morphine. Bayer's labs discovered heroin, barbiturates, aspirin & Tylenol. They sold all except Tylenol—considered too dangerous.What is pharmakeia in the Bible?Liberal white woman says Trump supporters are TERRIFIED of how big the “No Kings” protest 2.0 will be..  Does anyone else not give af..??Kaitlin Bennett went to a No Kings Rally in OrlandoData Republican is tracking the funders of the No Kings RallySome of David Black's “sermons” Countering Domestic Terrorism and Organized Political ViolenceUS Border Commander Greg Bovino, spearheading illegal alien roundups in Chicago, just posted this video of the locals absolutely LOVING his presence.